Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.47 |
| ▸ | PPARD | Q03181 | 12/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12741011 | 0.96 | FFAR1 (0.47) | FFAR1PPARDPPARAPPARGPTPN2 | |
| SCHEMBL12740528 | 0.94 | PPARD (0.54) | FFAR1PPARDPPARAPPARGPTPN2 | |
| SCHEMBL12717085 | 0.90 | FFAR1 (0.42) | FFAR1PPARDPPARAPPARGPTPN2 | |
| SCHEMBL12717072 | 0.89 | FFAR1 (0.40) | FFAR1PPARDPPARAPPARGTUBB1 | |
| SCHEMBL10302273 | 0.89 | TUBB1 (0.44) | FFAR1PPARDPPARAPPARGTUBB1 | |
| SCHEMBL12740976 | 0.88 | FFAR1 (0.44) | FFAR1PPARDPPARAPPARGTACR2 | |
| SCHEMBL14767069 | 0.87 | FFAR1 (0.54) | FFAR1PPARDPPARAPPARGPTGES | |
| SCHEMBL12736498 | 0.87 | TACR2 (0.41) | FFAR1PPARDPPARAPPARGPTPN2 | |
| SCHEMBL12740943 | 0.87 | TACR2 (0.41) | FFAR1PPARDPPARAPPARGPTPN2 | |
| SCHEMBL10302298 | 0.87 | FFAR1 (0.40) | FFAR1PPARDPPARAPPARGPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR1 247/4885PPARD 3762/4885PPARA 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.